Joao Ribas

Biotech VC & company builder. On a mission to invest in and help build disrupting biotech companies 🚀 ✦ Host of @futurelabspod podcast ✦ CBO at Orbis Medicines

[Joao Ribas @RibasJC]

Happy to announce the launch of Orbis Medicines! Learn more at https://t.co/k5eU28uAG6

[Novo Holdings @novoholdings]

Novo Holdings is proud to announce the launch and €26 million seed financing of Orbis Medicines, a leader in oral macrocycle drug development. Alongside European life sciences venture firm Forbion, this funding will support Orbis’ expansion and advancement of its portfolio of next-generation macrocycle drugs it calls ‘nCycles’. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties, defined by the presence of a cyclic structure. Orbis’ website can be found at: https://t.co/tB2HJNQHCH.

Orbis was founded in 2021 by the Seeds Investment team of Novo Holdings, with Morten Graugaard Døssing as Executive Chair and João Ribas as interim CBO establishing the company’s team and building its corporate strategy.

We look forward to supporting Orbis pioneer a new era for oral macrocycle drug discovery!

https://t.co/0QCGHq0T1t

[Novo Holdings @novoholdings]

San Francisco will be our home base this week as we meet with companies and investment partners from across the globe. We support companies in the US, Europe and Asia, across the life sciences continuum from very early-stage Seed investments, through the Ventures and Growth stages and into Principal (buyout) investments. With an annual capital deployment target of USD $3 billion, we’re looking forward to a productive #JPM2024 week.

[Joao Ribas @RibasJC]

If you're in biotech this needs to be on your list every year. Fantastic analysis and review @LifeSciVC

[Bruce Booth @LifeSciVC]

2023 is almost over... we just finished our Annual Mtg with our LP's and our Atlas Retreat with industry leaders... so it's time to share.

Here's our Atlas Venture 2023 "Year In Review"

#Biotech @Atlasventure
https://t.co/O92gPnT50j
https://t.co/7UEBkguddq

[Joao Ribas @RibasJC]

@Jack_O_Meara @snowmaker @ycombinator @LongwoodFund A good starting point would be the TTO-VC early stage TS (see end of page here https://t.co/xRyoc460jV). It's been co-signed by many VCs and reviewed by multiple TTOs. Maybe we need something like this for pharma partnerships so that we focus on science and value.

[Joao Ribas @RibasJC]

@nimivashi15 We use these tools internally. But I've seen multiple companies providing data analytics services to help achieve similar things.

[Joao Ribas @RibasJC]

@nimivashi15 I've built data analytics approaches to help me find groundbreaking science, wherever it comes from.

[Joao Ribas @RibasJC]

One of the most exciting uses of large language models is to help us learn more efficiently. Inspiring to see what it can do - a personalized tutor always available!
https://t.co/rvaKWkCTcJ

[Joao Ribas @RibasJC]

Congrats @CellReproLab !!

[Pereira Lab @CellReproLab]

I am excited to be granted the @novonordiskfond Distinguished Innovator Award!🎉 The grant of DKK 6 million will fuel @CellReproLab for 3 years to identify novel transcription factor networks for immune cell #reprogramming! /FP

#innovation @Lund_Stem @LuWcmm @lunduniversity

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Top product forecasts for 2023 https://t.co/XUmnGptBkf - a new analysis of the expected top-selling products next year @ByAmyBrown @EvaluatePharma, places the immune checkpoint inhibitor Keytruda at the top

[Bruce Booth @LifeSciVC]

Here’s the Atlas Venture 2022 Year In Review.

This year, given the 2+ year rollercoaster in the mkts, we start with a deep dive into both the public and private #biotech capital markets, then to the industry overall, closing with an update on ⁦Atlas https://t.co/HJ8zEXabyM

[Joao Ribas @RibasJC]

Only @SaraNayeem could make a thread about footnotes that's insightful and helpful to biotech execs.

[Sara Nayeem @SaraNayeem]

For biotech execs raising private capital, an easy way to increase the perceived “rigor” of your deck is to go through and add footnotes anywhere something isn’t entirely clear or straightforward. The beauty of footnotes is that investors can choose whether to read them. 1/4

[Asgard Therapeutics @AsgardThx]

Check out the newest feature in @bpdealmakers that selected @AsgardThx platform technology as an innovative gene therapy to reprogram anti-cancer immunity. #Immunotherapy #biopharma https://t.co/HRifH2j3Gl

[Joao Ribas @RibasJC]

Wow! Brilliant idea and execution!

[Mike Tyka (@[email protected]) @mtyka]

I'm very happy to finally reveal this sculpture. Two years in the making (together with https://t.co/V1y9nFtcH8) and under embargo as it was a surprise for my former postdoc adviser David Baker. https://t.co/13lgR6lkXL

[Bruce Booth @LifeSciVC]

An Experimental Gene Therapy Changed His DNA—And His Hair Color - The Atlantic. $AVRO https://t.co/497f8ff0yk

[Joao Ribas @RibasJC]

@_CristianaPires this may be helpful!

[Sara Nayeem @SaraNayeem]

Fabulous content! Highly recommend.

[Joao Ribas @RibasJC]

@aloktayi @AleksEngel could tell you all about a new model for companies in the antimicrobial resistance space!

[Joao Ribas @RibasJC]

📢 Excited to announce our latest @novoholdings investment - Engimmune Therapeutics - a company pioneering novel TCR-based therapies using a cutting-edge TCR engineering platform 📢 #biotech #VentureCapital

[Novo Holdings @novoholdings]

Engimmune Therapeutics AG, a biotech company developing novel T-cell receptor (TCR)-based therapeutics, announced today the completion of a CHF 15.5 million (EUR 15.2 m / USD 16.7 m) seed financing round, co-led by Pureos Bioventures and Novo Holdings.
https://t.co/dAlaNZNj6v

[Joao Ribas @RibasJC]

Launching 𝘥𝘦 𝘯𝘰𝘷𝘰 - a Novo Seeds blog on biotech. The first article is about the role of entrepreneurs-in-residence in venture creation, from a VC and EiR perspective. What other topics would you like to read about? @novoholdings
https://t.co/ixTQW9XFqK

[Joao Ribas @RibasJC]

I'm a big fan and proponent of the "investment highlights" slide! Super helpful to get the bigger picture and convey the message at Partner meetings.

[Sara Nayeem @SaraNayeem]

...(differentiation; market size; pipeline; etc.) – you will end up using this in other settings. Finally, getting to the deck – consider an investment highlights page that lays out some general high-level thesis points about the company. Build on these throughout the...4/9

[Joao Ribas @RibasJC]

Proud to announce the acquisition of our portfolio company @syndesi_tx! It's been super exciting to be part of this journey and to witness the company development over the years 🚀

[Novo Holdings @novoholdings]

Novo Holdings today announces that its portfolio company @syndesi_tx has been acquired by @abbvie $ABBV for up to US$1 billion in total deal value with US$ 130 million upfront.
https://t.co/3N7WEud3Zf